• 1
    Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastases. Cell 1994;79: 1858.
  • 2
    Fidler IJ. Critical determinants of melanoma metastasis. J Invest Dermatol 1996;1: 2038.
  • 3
    Li WW, Grayson G, Folkman J, D'Amore PA. Sustained-release endotoxin. A model for inducing corneal neovascularization. Invest Ophthalmol Vis Sci 1991;32: 290611.
  • 4
    Mattsby-Baltzer I, Jakobsson A, Sörbo J, Norrby K. Endotoxin is angiogenic. Int J Exp Path 1994;75: 1916.
  • 5
    Garcia FU, Wojta J, Broadley KN, Davidson JM, Hoover RL. Bartonella bacilliformis stimulates endothelial cells in vitro and is angiogenic in vivo. Am J Pathol 1990;136: 112535.
  • 6
    Majno G. Chronic inflammation. Links with angiogenesis and wound healing. Am J Pathol 1998;153: 10359.
  • 7
    Howe LR, Subbaramaiah K, Brown AMC, Dannenberg AJ. Cyclooxygenase-2: a target for the prevention and treatment of breast cancer. Endocrine-Related Cancer 2001;8: 97114.
  • 8
    Rylander R, Bake B, Fischer J, Helander I. Pulmonary function and symptoms after inhalation of endotoxin. Am Rev Respir Dis 1989;140: 9816.
  • 9
    Pidgeon GP, Harmey JH, Kay E, Da Costa M, Redmond HP, Bouchier-Hayes DJ. The role of endotoxin/lipopolysaccharide in surgically induced tumor growth in a murine model of metastatic disease. Br J Cancer 1999;81: 13117.
  • 10
    Watson RWG, Redmond HP, McCarthy J, Burke PE, Bouchier-Hayes D. Exposure of the peritoneal cavity to air regulates early inflammatory responses to surgery in a murine model. Br J Surg 1995;82: 10605.
  • 11
    Djikstra HM, Manson WL, Blaauw B, Klasen HJ, de Smet B. Bacterial translocation in D-galactosamine-treated rats in a burn model. Burns 1996;22: 1521.
  • 12
    Kakkos SK, Kirkilesis J, Scopa CD, Arvaniti A, Alexandrides T, Vagianos CE. Nonabsorbable antibiotics reduce bacterial and endotoxin translocation in hepatectomised rats. HPB Surg 1997;10: 2839.
  • 13
    Leung DW, Cachienes G, Kuang WJ, Goeddel DV, Ferrara N. 1989. VEGF is a secreted angiogenic mitogen. Science 1989;246: 13069.
  • 14
    Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219: 9835.
  • 15
    McDougall JR, Matrisian LM. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 1995;14: 35162.
  • 16
    Bruns CJ, Shinohara H, Harbison MT, Davis DW, Nelkin G, Killion JJ, McConkey DJ, Dong Z, Fidler IJ. Therapy of human pancreatic carcinoma implants by irinotecan and the oral immunomodulator JBT 3002 is associated with enhanced expression of inducible nitric oxide synthase in tumor-infiltrating macrophages. Cancer Res 2000;60: 27.
  • 17
    Wu J, Akaike T, Hayashida K, Okamoto T, Okuyama A, Maeda H. Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinase. Jpn J Cancer Res 2001;92: 43951.
  • 18
    Liao W. Endotoxin: possible roles in initiation and development of atherosclerosis. J Lab Clin Med 1996;128: 45260.
  • 19
    Jadeski LC, Hum KO, Chakraborty C, Lala PK. Nitric oxide promotes murine mammary tumor growth and metastasis by stimulating tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2000;86: 309.
  • 20
    Xie K, Huang S, Dong Z, Juang S-H, Gutman M, Xie QW, Nathan C, Fidler IJ. Transfection with the inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis by K-1735 murine melanoma cells. J Exp Med 1995;181: 133343.
  • 21
    Dvorak HF, Nagy JA, Dvorak JT, Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 1988;133: 95109.
  • 22
    Thurston G, Suri C, Smith K, McClain J, Sato TN, Yancopoulos GD, McDonald DM. Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. Science 1999;286: 25114.
  • 23
    Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, Fidler IJ. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 2000;16: 44554.
  • 24
    Leppink DM, Bishop DK, Sedmark DD, Henry ML, Ferguson RM. Inducible expression of an endothelial cell antigen on murine myocardial vasculature in association with interstitial cellular infiltration. Transplantation 1989;48: 8747.
  • 25
    Yano S, Herbst RS, Shinohara H, Knighton B, Bucana CD, Killion JJ, Wood J, Fidler IJ. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation. Clin Cancer Res 2000;6: 95765.
  • 26
    Harmey JH, Pidgeon GP, McNamara DA, Bouchier-Hayes D. Lipopolysaccharide increases vascular endothelial growth factor production by macrophages and tumor cells. FASEB J 1998;166(suppl 8): 432.
  • 27
    Irie K, Fujii E, Ishida H, Wada K, Suganuma T, Nishikori T, Yoshioka T, Muraki T. Inhibitory effects of cyclic AMP elevating agents on lipopolysaccharide (LPS)-induced microvascular permeability change in mouse skin. Br J Pharmacol 2001;133: 23742.
  • 28
    Corbel M, Lagente V, Théret N, Germain N, Clement B, Boichot E. Comparative effects of betamethasone, cyclosporin and nedcromil sodium in acute pulmonary inflammation and metalloproteinase activities in bronchoalveolar lavage fluid from mice exposed to lipopolysaccharide. Pulmon Pharmacol Therapeut 1999; 12: 16571.
  • 29
    Luzzi KJ, McDonald IC, Schmidt EE, Kerkvliet N, Morris VL, Chambers AF, Groom AC. Multistep nature of metastatic inefficiency. Dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998;153: 86573.
  • 30
    Orucevic A, Bechberger J, Green AM, Shapiro RA, Billiar TR, Lala PK. Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. Int J Cancer 1999;81: 88996.
  • 31
    Fukumura D, Gohongi T, Kadambi A, Izumi Y, Ang J, Yun C-O, Buerk DG, Huang PL, Jain RK. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 2001;98: 26049.
  • 32
    Wang B, Xiong Q, Shi Q, Tan D, Le X, Xie K. Genetic disruption of host nitric oxide synthase II gene impairs melanoma-induced angiogenesis and suppresses pleural effusion. Int J Cancer 2001;91: 60711.
  • 33
    Lala PK, Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001;2: 14956.
  • 34
    Von Knethen A, Brüne B. Cyclooxygenase-2: an essential regulator of NO-mediated apoptosis. FASEB J 1997;11: 88795.
  • 35
    Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase inhibitors. Cancer Res 2000;60: 130611.
  • 36
    Lee SH, Soyoola E, Chanmugam P, Hart S, Sun W, Zhong H, Liou S, Simmons D, Hwang D. Selective expression of mitogen-inducible cyclooxygenase in macrophages stimulated with lipopolysaccharide. J Biol Chem 1992;267: 259348.
  • 37
    Connolly EM, Harmey JH, O'Grady T, Foley D, Roche-Nagle G, Kay E, Bouchier-Hayes D. Cyclo-oxygenase inhibition reduces tumour growth and metastasis in an orthotopic model of breast cancer. Br J Cancer, 2002;87: 2317.
  • 38
    Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 2002;62: 16570.
  • 39
    Berg RD. Bacterial translocation from the gastrointestinal tract. J Med 1992;23: 21744.